Home › New KEYTRUDA (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival Data, To Be Presented at 2016 ASCO Annual Meeting
 

Keywords :   


New KEYTRUDA (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival Data, To Be Presented at 2016 ASCO Annual Meeting

2016-06-04 14:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. New Analysis from KEYNOTE-010, Comparing KEYTRUDA to Chemotherapy, Shows Improved Survival Benefit in Patients with Increased Levels of PD-L1 Expression KEYNOTE-001 Findings Show Responses Are Durable and Include Two Year Overall Survival Data for KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data, including updated response rates, progression-free survival (PFS) and overall survival (OS) with KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy in patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1 from two studies: KEYNOTE-010 and KEYNOTE-001. Language: English Contact: MerckMedia Contacts:Pamela Eisele, (267) 305-3558orCourtney Ronaldo, (908) 236-1108orInvestor Contacts:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: including data advanced presented

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.05'Garden floods show need to work with nature'
03.05Worst-ever job interviews: 'We had to crawl and moo'
03.05Have the wheels come off for Tesla?
03.05BW Converting focuses on time, energy and cost savings at INFOFLEX
03.05Navigator Paper Ups Offer for Accrual
03.05USDA urged to restore NASS surveys
03.05Dilo Hosts Open House
03.05Spate Releases Top-Rising Skin Care Ingredients Report with Grant Industries
More »